Joseph P. Lyssikatos, Chief Scientific Officer: Enliven Therapeutics ELVN Planned sale · Filed 03/31

Trade details

Type: Planned sale notice
Stock: Enliven Therapeutics ELVN
Person: Joseph P. LyssikatosChief Scientific Officer
Planned sale date: 26/03/31
Filed: 26/03/31

More to sell after $6.1M in 3 months

Enliven Therapeutics trades, last 26 weeks

What else happened in Enliven Therapeutics around then

Filed or reported within 30 days of the trade day · 03/01~04/30

Joseph P. Lyssikatos's recent trades

Joseph P. LyssikatosChief Scientific Officer
Planned sale10b5-1 planEnliven Therapeutics
Planned sale10b5-1 plan
Enliven Therapeutics
ELVN
$1.1M
25,000 sh
$1.1M
Filed 04/30
Traded 04/30
Joseph P. LyssikatosChief Scientific Officer
Planned sale10b5-1 planEnliven Therapeutics
Planned sale10b5-1 plan
Enliven Therapeutics
ELVN
$2M
75,000 sh
$2M
Filed 02/18
Traded 02/18
Joseph P. LyssikatosChief Scientific Officer
Sell10b5-1 planEnliven Therapeutics
Sell10b5-1 plan
Enliven Therapeutics
ELVN
$145.2K
5,000 sh
$145.2K
Filed 02/10
Traded 02/06
Joseph P. LyssikatosChief Scientific Officer
Sell10b5-1 planEnliven Therapeutics
Sell10b5-1 plan
Enliven Therapeutics
ELVN
$390.3K
14,509 sh
$390.3K
Filed 01/22
Traded 01/20
Joseph P. LyssikatosChief Scientific Officer
Sell10b5-1 planEnliven Therapeutics
Sell10b5-1 plan
Enliven Therapeutics
ELVN
$144.8K
5,491 sh
$144.8K
Filed 01/22
Traded 01/20

Joseph P. Lyssikatos, Chief Officer — plans to sell 25,000 sh of Enliven Therapeutics ELVN · $914.8K · around 03/31 · 10b5-1 plan | Whalegun